Key Insights

Highlights

Treatment Research

5 treatments under study, led by Pemetrexed Cisplatin Carboplatin

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2/3 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT07365319Phase 2/3Recruiting

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

Showing all 1 trials

Research Network

Common Treatments

  • Pemetrexed Cisplatin Carboplatin1
  • Nabpaclitaxel Carboplatin1
  • Paclitaxel Carboplatin1
  • Eik10011
  • Pembrolizumab1

Active Sponsors

  • Eikon Therapeutics Inc.1
  • Merck Sharp & Dohme LLC1
  • Eikon Therapeutics1

Top Investigators

Related Conditions

  • Non Small Cell Lung Cancer Squamous Or Non Squamous1
  • Stage 4 Nsclc1

Activity Timeline